


CZC-25146

11/19

ALTERNATE NAMES: N-[2-[[5-Fluoro-2-(2-methoxy-4-morpholin-4-yl)anilino]pyrimidin-4-yl]amino]phenyl]methanesulfonamide;
 N-[2-[[5-fluoro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-
 methanesulfonamide

CATALOG #: B2941-5 5 mg
 B2941-25 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₂₂H₂₅FN₆O₄S

MOLECULAR WEIGHT: 488.54

CAS NUMBER: 1191911-26-8

APPEARANCE: A crystalline solid

PURITY: >98%

SOLUBILITY: ~10 mg/ml in DMSO and DMF

DESCRIPTION: CZC-25146 is a potent inhibitor of Leucine-rich repeat kinase 2 (LRRK2) with an IC₅₀ of 4.76 nM. Mutations in LRRK2 are associated with Parkinson's disease. CZC-25146 attenuates LRRK2 G2019S mutant induced neuronal injury with EC₅₀ values of ~100 nM and 4 nM in primary rodent and human neurons respectively.

STORAGE TEMPERATURE: -20°C

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCE: Ramsden, N.G., Perrin, J., Ren, Z., et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol. 6(10), 1021-1028 (2011).

RELATED PRODUCTS:

HG-10-012-01 (Cat. No. 2604)
 PF-06447475 (Cat. No. 9447)
 CZC-54252 hydrochloride (Cat. No. 9567)
 LRRK2-IN-1 (Cat. No. B2940)
 GSK2578215A (Cat. No. 2845)

DISCLAIMER: ***FOR RESEARCH USE ONLY! Not to be used on humans.***